Massimo Volpe
University of Zurich
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Massimo Volpe.
Journal of Hypertension | 2002
Francesco Cosentino; Sandro Bonetti; Rudolf Rehorik; Masato Eto; Gabriele Werner‐Felmayer; Massimo Volpe; Thomas F. Lüscher
Background Nebivolol is a new β1-selective adrenergic receptor antagonist with a direct vasorelaxant effect that involves activation of the l-arginine–nitric oxide (NO) pathway. Therefore, treatment with nebivolol may protect against endothelial injury in hypertension. Objective To investigate whether chronic selective β1-blockade with nebivolol could prevent endothelial dysfunction in salt-induced hypertension, and to compare it with atenolol. Methods Dahl salt-sensitive rats were treated for 8 weeks with standard chow or chow containing 4% NaCl alone or in combination with nebivolol (10 mg/kg per day) or atenolol (100 mg/kg per day). Isometric tension was continuously recorded in isolated aorta and small mesenteric arteries. Constitutive NO synthase (cNOS) activity was determined by [3H]citrulline assay. Results Chronic salt administration increased systolic blood pressure by 38 ± 5 mmHg in salt-treated rats as compared with that in control rats. Both nebivolol and atenolol prevented a salt-induced increase in pressure. cNOS activity was significantly decreased by a high-salt diet. The impairment of endothelium-dependent relaxations in response to acetylcholine in salt-treated rats was prevented only by nebivolol, in both large and small arteries. In contrast, the reduced endothelium-independent relaxations and contractions in response to sodium nitroprusside and endothelin-1, respectively, were restored by both drugs. Nebivolol, but not atenolol, restored cNOS activity. Conclusions Despite nebivolol and atenolol having the same blood-pressure-decreasing effect, only nebivolol was able to prevent endothelial dysfunction. This study demonstrates for the first time that the acute NO-mediated vasodilatory action of nebivolol is also present during chronic treatment. Hence, nebivolol might become a new therapeutic tool with which to exert vascular protective effects against end-organ damage in conditions associated with NO deficiency.
Ipertensione e Prevenzione Cardiovascolare | 2013
Massimo Volpe; Ettore Ambrosioni; Claudio Borghi; Santina Cottone; Cesare Cuspidi; Nicola De Luca; Francesco Fallo; Claudio Ferri; Alberto Morganti; Maria Lorenza Muiesan; Riccardo Sarzani; Leonardo Sechi; Agostino Virdis; Giuliano Tocci; B. Trimarco; Alessandro Filippi; Giuseppe Mancia
Archive | 2018
Francesco Paneni; Massimo Volpe
Archive | 2014
Massimo Volpe; Giuliano Tocci
Ipertensione e Prevenzione Cardiovascolare | 2014
Giuliano Tocci; Nicola De Luca; Riccardo Sarzani; Ettore Ambrosioni; Claudio Borghi; Santina Cottone; Cesare Cuspidi; Francesco Fallo; Claudio Ferri; Alberto Morganti; Maria Lorenza Muiesan; Leonardo Sechi; Agostino Virdis; Giuseppe Mancia; Massimo Volpe
Archive | 2013
Silvia Riondino; Susanna Grego; Massimo Volpe; Francesco Violi; Pasquale Pignatelli; Luisa Lenti; Giuliano Tocci; Alessandra Brunelli
Archive | 2013
Francesco Paneni; Massimo Volpe; Thomas F. Lüscher; Francesco Cosentino
American Heart Association (AHA) 2013 Scientific Sessions | 2013
Massimo Volpe; Francesco Cosentino; Thomas F. Lüscher; Lorenzo Castello; Sergio Chiandotto; Sarah Costantino; Francesco Paneni; Rodolfo Battista; Giuliana Capretti
American Heart Association (AHA) 2013 Scientific Sessions | 2013
Massimo Volpe; Lorenzo Castello; Sergio Chiandotto; Francesco Cosentino; Francesco Paneni; Sarah Costantino; Thomas F. Lüscher; Rodolfo Battista; Giuliana Capretti
Archive | 2012
Giuliano Tocci; Francesco Paneni; Jasmine Passerini; Massimo Volpe